West Pharmaceutical Services appoints new CFO, Robert McMahon, effective Aug 4.

• West Pharmaceutical Services appoints Robert McMahon as new CFO, effective August 4, 2025. • McMahon succeeds Bernard Birkett, who announced his retirement earlier this year. • Birkett will remain as Senior Advisor to the CEO through year-end for a smooth transition. • McMahon has a 34-year career in the healthcare industry with a proven track record of financial success. • He will lead the company through dynamic environments and implement effective financial strategies.

West Pharmaceutical Services, Inc. (NYSE: WST) has appointed Robert McMahon as its new Chief Financial Officer (CFO), effective August 4, 2025. McMahon will succeed Bernard Birkett, who announced his intention to retire earlier this year. Birkett will assume the role of Senior Advisor to the CEO through the end of 2025 to ensure a smooth transition [1].

McMahon, an accomplished CFO with a 34-year career in the healthcare industry, brings a proven track record of delivering strong financial results and implementing effective financial and operational strategies. Prior to his appointment at West, McMahon served as the CFO of Agilent Technologies Inc. since 2018. He previously held executive financial roles at Hologic, Inc. and Johnson & Johnson. Additionally, he has served as an Independent Director at OraSure Technologies, Inc. since 2023 [1].

"I'm excited by the opportunity to join such a well-positioned company with a talented team dedicated to improving patient health," said Mr. McMahon. "With a history of innovation spanning more than a century, I look forward to working alongside Eric and the leadership team to play a meaningful role in charting the next chapter of West's growth story for all stakeholders" [1].

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. With over 10,000 team members across 50 sites, including 25 manufacturing facilities worldwide, West supports its customers by delivering over 41 billion components and devices each year. In fiscal year 2024, the company generated $2.89 billion in net sales [1].

The appointment of McMahon comes at a time when the financial markets have experienced significant volatility. Despite a dramatic 22% drop following "Liberation Day" on April 2nd, the S&P 500 has seen a 6.20% year-to-date performance. West Pharmaceutical Services, Inc. has been highlighted by investment management companies like Brasada Capital Management for its potential as an investment, although certain AI stocks have been identified as offering greater upside potential [2].

West Pharmaceutical Services, Inc. has been recognized for its strong corporate governance, with the company listed in the Top Ten Corporate Governance Quotient Ranking in the Russell 3000 Index by Institutional Shareholders Services [3]. The company's leadership team includes Eric M. Green, President and Chief Executive Officer, who has led the company since 2015, and Bernard J. Birkett, who will transition to Senior Advisor to the CEO through the end of the year [3].

As West Pharmaceutical Services, Inc. continues to navigate dynamic financial environments, McMahon's leadership and expertise will be instrumental in guiding the company forward and generating long-term shareholder value.

References:
[1] https://www.prnewswire.com/news-releases/west-welcomes-robert-mcmahon-as-incoming-chief-financial-officer-302508951.html
[2] https://finance.yahoo.com/news/west-pharmaceutical-services-wst-great-112219349.html
[3] https://investor.westpharma.com/corporate-governance